European Society of Gynaecological Oncology
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030
The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China
AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US
AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer
Around one in five breast cancer cases are HER2-positive
AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers
In 2022, nearly one million new patients were diagnosed with gastric cancer
AstraZeneca announces $2bn investment in US manufacturing
The new and expanded facilities will support production of rare disease drug treatments
AstraZeneca reports positive results from rare disease trial
HES is a group of rare disorders characterised by persistently elevated levels of white blood cells
AstraZeneca reports positive results from phase 3 blood pressure trial
The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension